Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07018713 · ClinicalTrials.gov registry record · Phase 3

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

A Phase 3 study of Chronic Migraine, sponsored by Merz Therapeutics.

Recruiting
Registry status
Phase 3
Development phase
780
Enrollment target
20
Study locations

NCT07018713: Recruiting Phase 3 study of Chronic Migraine, sponsored by Merz Therapeutics.

NCT07018713 is a Phase 3 study of Chronic Migraine that is actively recruiting participants, run by Merz Therapeutics. The registered enrollment target is 780 participants, above the 298-participant average among 17 other Chronic Migraine trials with a reported enrollment target (162% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07018713, a Phase 3 study of Chronic Migraine, is actively recruiting participants, sponsored by Merz Therapeutics.

RECRUITING
Registry status
Phase 3
Development phase
780 participants
Enrollment target
20
Study locations

Study Summary

In this clinical trial, participants with chronic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections. Trial details include: * Trial duration: 52 to 55 weeks; * Screening period: 4 to 5 weeks; * Treatment duration: 4 treatments, each about 12 weeks apart; and * Visit frequency: about every 4 weeks, 14 visits in total. The first and last visit and the 4 treatment visits are on-site, the other 8 visits are remote by phone / video call.

Conditions Studied

Chronic Migraine

Interventions

  • DRUG Placebo
  • DRUG Xeomin

Study Locations (20)

Florida

  • Northwest Florida Clinical Research Group, Merz Investigational Site #0010286 - Gulf Breeze
  • Nexus Clinical Research Center, Merz Investigational Site #0010514 - Homestead
  • Jacksonville Center for Clinical Research, Merz Investigational Site #0010515 - Jacksonville
  • Clinical Research of Central Florida, Merz Investigational Site #0010532 - Lakeland
  • American Research Institute, Merz Investigational Site #0010492 - Miami
  • Premiere Research Institute at Palm Beach Neurology, Merz Investigational Site #0010499 - West Palm Beach

California

  • Chemidox Clinical Trials Inc, Merz Investigational Site #0010488 - Lancaster
  • Clinical Research Institute, Merz Investigational Site #0010487 - Los Angeles
  • BNL Health, Merz Investigational Site #0010501 - Los Angeles
  • Clinical Trials Management Services, Merz Investigational Site #0010526 - Thousand Oaks

Connecticut

  • Hasbani Neurology, Merz Investigational Site #0010509 - New Haven
  • Yale Center for Clinical Investigations, Merz Investigational Site #0010527 - New Haven
  • New England Institute Neurology and Headache, Merz Investigational Site #0010441 - Stamford

Arizona

  • TrialSphere Corp, Merz Investigational Site #0010513 - Chandler
  • Arizona Neuroscience Research, Merz Investigational Site #0010521 - Phoenix

Arkansas

  • Baptist Health Medical Center, Merz Investigational Site #0010520 - Little Rock

Georgia

  • Accel Research - NeuroStudies, Merz Investigational Site #0010523 - Decatur

Hawaii

  • Hawaii Pacific Neuroscience, Merz Investigational Site #0010510 - Honolulu

Kansas

  • Kansas Institute of Research,, Merz Investigational Site #0010495 - Overland Park

Trial Details

FieldValue
Enrollment Target 780 participants
Start Date 2025-08-21
Est. Completion 2028-03
Phase Phase 3
Merz Therapeutics

2 total trials

What NCT07018713 shows while recruiting

NCT07018713 is an interventional study that assigns participants to a tested intervention. The registered 780 participants enrollment target is mid-sized for trials with a published cap, above the 298-participant average among 17 other Chronic Migraine trials with a reported enrollment target (162% higher).

The record links to 1 condition, with Chronic Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07018713 names 20 study sites across 9 states, led by Florida, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT07018713 about?

NCT07018713 is a clinical study titled "A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine". In this clinical trial, participants with chronic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections. Trial details include: * Trial duration:...

What is the current status of trial NCT07018713?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 780 participants. The study started on 2025-08-21. Estimated completion is 2028-03.

What conditions does trial NCT07018713 study?

This clinical trial studies the following conditions: Chronic Migraine.

What interventions are being tested in trial NCT07018713?

The interventions under investigation include: Placebo (DRUG), Xeomin (DRUG).

Who is sponsoring clinical trial NCT07018713?

This trial is sponsored by Merz Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07018713 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Migraine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07018713's enrollment target sits among peer trials

780 2nd of 17 the highest of 17 other Chronic Migraine trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05046613 · 780 participants

    Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

  • NCT05100862 · 780 participants · Phase 3

    A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

  • NCT05513872 · 780 participants · Phase 1

    Overcoming Nicotine Dependence to Enable Quitting

  • NCT06310031 · 780 participants · NA

    Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07018713

Source: ClinicalTrials.gov NCT07018713, the US trial registry maintained by the National Library of Medicine. NCT07018713 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.